Stem cell exosome injections for a thin uterine lining in women with infertility
Tests exosomes from umbilical cord stem cells against platelet-rich plasma in women with thin endometrium.
Key facts
- Who runs it
- Tang-Du Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 90 people, planned
- Started
- 21 Feb 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes
- Umbilical cord mesenchymal stem cell-derived exosomes
- platelet-rich plasma
- Record updated
- 26 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with a thin womb lining after surgery for scar tissue inside the womb, who plan to keep trying IVF or embryo transfer.
- Age
- 20 to 40 years
- Sex
- Women only
- Disease stage
- Thin womb lining: under 7 mm in at least one embryo transfer cycle with standard hormone treatment. Ovaries must work normally (AFC ≥ 7, AMH > 1.1 ng/mL).
- Earlier treatment
- Must have had surgery to remove scar tissue in the womb (TCRA), then PRP treatment. Must have had at least one embryo transfer cycle.
- Biomarker or test result
- AFC ≥ 7 and AMH > 1.1 ng/mL
Main reasons for not taking part
- Severe body-wide disease, or cannot have surgery or anesthesia
- Infection of the reproductive organs, genital tuberculosis, pelvic inflammation, or cancer of the reproductive organs
- High risk of hormone-dependent tumors such as breast cancer or ovarian tumors
- Untreated fibroids inside the womb, fibroids ≥5 cm (2 in), adenomyosis, womb shape problems, or polyps
- Fluid-filled tubes ≥3 cm (1.2 in), ovarian chocolate cysts ≥4 cm (1.6 in), or genetic abnormalities
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Females aged 20-40 years (inclusive of boundary values)
- Normal ovarian reserve function (criteria: AFC ≥ 7, AMH > 1.1 ng/mL)
- History of transcervical resection of adhesions (TCRA)
- Received PRP treatment after TCRA
- At least one embryo transfer (ET) cycle in which they underwent standard ovarian stimulation (fresh cycle) or standard hormone replacement therapy (FET cycle), with an endometrial thickness of <7 mm
- Planned to continue IVF/ICSI/FET-assisted conception
- Able to accept and adhere to treatment and follow-up and willing to sign an informed consent form
Who cannot take part
- Patients who participated in other clinical trials within 3 months before surgery or during the study period
- Patients with severe systemic diseases, surgical contraindications, or cycle contraindications
- Patients with reproductive tract infections, genital tuberculosis, pelvic inflammatory disease, or malignant tumors of reproductive organs
- Patients with systemic diseases that cause uterine bleeding
- Patients allergic to any drugs, materials, or components used in this study
- Patients at high risk for hormone-dependent tumors such as breast cancer or ovarian tumors
- Patients with untreated submucosal fibroids of any size (FIGO 0/I/II), uterine fibroids ≥5 cm (FIGO III, IV, V, VI, VII), adenomyosis, unicornuate uterus, bicornuate uterus, or endometrial polyps
- Patients with hydrosalpinx ≥3 cm or hydrosalpinx of any size with significant vaginal discharge
- Patients with ovarian endometriotic cysts (chocolate cysts) ≥4 cm
- Patients unable to tolerate anesthesia
- Patients with genetic abnormalities
- Other patients deemed unsuitable for participation in this study by the investigator
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate if engineered mechanically umbilical cord-derived stem cell exosomes, or conventional umbilical cord -derived stem cell exosomes, can improve endometrial thickness in women with thin endometrium.
Read full original descriptionShow less
The main questions it aims to answer are:
Can exosomes delivered via subendometrial injection improve endometrial thickness or clinical pregnancy rates compared to PRP (platelet-rich plasma)? Are there significant differences in endometrial thickness between the two treatment groups? Researchers will compare the intervention groups, which one group receives mechanical exosomes and the other receives conventional esosomes via subendometrial injection, to the control group, which receives PRP via the same methods, to see if exosomes provide superior therapeutic effects.
Participants will:
Receive either mechanical exosomesor or conventional esosomes or PRP through subendometrial injection.
Be monitored for changes in endometrial parameters.
The 3 groups in the trial
- Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosome Group (ME-UCMSC-Exo)Treatment being tested
Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) containing approximately 5×10¹⁰ particles/mL during the proliferative phase (Day 3-7 of the menstrual cycle). The exosomes are obtained from mechanically preconditioned UC-MSC cultures, which are subjected to biomechanical stress during expansion to enhance regenerative properties. The study aims to evaluate the efficacy of ME-UCMSC-Exo in improving endometrial thickness and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions.
Treatment: Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes
- Conventional Umbilical Cord Mesenchymal Stem Cell-Derived Exosome Group (UCMSC-Exo)Treatment being tested
Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL conventional umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) containing approximately 5×10¹⁰ particles/mL during the proliferative phase (Day 3-7 of the menstrual cycle). Unlike the ME-UCMSC-Exo group, these exosomes are obtained from standard UC-MSC cultures without mechanical stress preconditioning. This group serves as a comparator to determine whether mechanical preconditioning enhances exosome efficacy in endometrial regeneration and pregnancy outcomes.
Treatment: Umbilical cord mesenchymal stem cell-derived exosomes
- Platelet-Rich Plasma (PRP) Control GroupExisting treatment, for comparison
Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL autologous PRP following standard PRP preparation protocols during the proliferative phase (Day 3-7 of the menstrual cycle). PRP contains growth factors such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β), which have been shown to improve endometrial receptivity and pregnancy outcomes. This group serves as a positive control for assessing the efficacy of exosome-based therapies.
Treatment: platelet-rich plasma
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Therapeutic Effects of Mechanically Engineered Umbilical Cord-Derived Stem Cell Exosomes on Endometrial Injury: A Prospective, Non-Randomized, Parallel-Controlled Clinical Study
- Plain-language title
- Stem cell exosome injections for a thin uterine lining in women with infertilityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06896747, who can take part
- Record updated
- 26 March 2025